open access

Vol 12, No 1 (2018)
Review paper
Published online: 2018-05-02
Get Citation

Diabetic patient in palliative care

Aleksandra Modlińska
Palliat Med Pract 2018;12(1):11-20.

open access

Vol 12, No 1 (2018)
Review articles
Published online: 2018-05-02

Abstract

Diabetes management of the patients with advanced diseases is a significant task for palliative care team. First of all, the main aim is preservation of quality of life. Therapeutic and diet decisions should be provided on an appropriate level of intervention according to patient’s condition and prognosis. The pharmacologic therapy may include oral agents or/and insulin treatment. We should avoid metabolic de-compensation, like frequent and/or deep hypoglycaemia, symptomatic clinical dehydration, diabetic ketoacidosis, or per­sistent hyperglycaemia, especially in the case of chronic wounds, bed sores or cancer ulceration. Based on available publications, expert opinions and own experience, some glucose control target ranges and ways of making therapeutic decision in the context of limited life expectancy are suggested

Abstract

Diabetes management of the patients with advanced diseases is a significant task for palliative care team. First of all, the main aim is preservation of quality of life. Therapeutic and diet decisions should be provided on an appropriate level of intervention according to patient’s condition and prognosis. The pharmacologic therapy may include oral agents or/and insulin treatment. We should avoid metabolic de-compensation, like frequent and/or deep hypoglycaemia, symptomatic clinical dehydration, diabetic ketoacidosis, or per­sistent hyperglycaemia, especially in the case of chronic wounds, bed sores or cancer ulceration. Based on available publications, expert opinions and own experience, some glucose control target ranges and ways of making therapeutic decision in the context of limited life expectancy are suggested

Get Citation

Keywords

diabetes, palliative care, therapeutic decisions

About this article
Title

Diabetic patient in palliative care

Journal

Palliative Medicine in Practice

Issue

Vol 12, No 1 (2018)

Article type

Review paper

Pages

11-20

Published online

2018-05-02

Bibliographic record

Palliat Med Pract 2018;12(1):11-20.

Keywords

diabetes
palliative care
therapeutic decisions

Authors

Aleksandra Modlińska

References (32)
  1. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetol Prakt. 2017; 3(supl. A): A21-A23 A56–A57.
  2. Angelo M, Ruchalski C, Sproge BJ. An approach to diabetes mellitus in hospice and palliative medicine. J Palliat Med. 2011; 14(1): 83–87.
  3. McCoubrie R, Jeffrey D, Paton C, et al. Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care (Engl). 2005; 14(3): 244–248.
  4. McPherson ML. Management of diabetes at end of life. Home Healthc Nurse. 2008; 26(5): 276–278.
  5. Zylicz Z. Management of diabetes mellitus in terminally ill cancer patients. Adv Pall Med. 2010; 9: 99–102.
  6. Ford-Dunn S, Smith A, Quin J. [Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med. 2006; 20(3): 197–203.
  7. Poulson J. The management of diabetes in patients with advanced cancer. J Pain Symptom Manage. 1997; 13(6): 339–346.
  8. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. Diabetologia. 2005; 48(12): 2460–2469.
  9. Roberts RO, Knopman DS, Przybelski SA, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology. 2014; 82(13): 1132–1141.
  10. International Diabetes Federation Working Group: Managing older people with type 2 diabetes; global guideline. Bruksela, International Diabetes Federation Bruksela, 2013.
  11. Płaczkiewicz–Jankowska E, Czupryniak L. Postępowanie u chorych na cukrzycę typu 2 w wieku podeszłym: podsumowanie wytycznych International Diabetes Federation 2013 – cz. II. Med Prakt. 2014; 5: 40–45.
  12. Pickering D, Marsden J. How to measure blood glucose. Community Eye Health. 2014; 27(87): 56–57.
  13. 11. Older Adults: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2017; 41(Supplement 1): S119–S125.
  14. Nathan DM, Kuenen J, Borg R, et al. A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008; 31(8): 1473–1478.
  15. Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol. 2012; 69(9): 1170–1175.
  16. Poulson J. The management of diabetes in patients with advanced cancer. J Pain Symptom Manage. 1997; 13(6): 339–346.
  17. Usborne C, Wilding J. Treating diabetes mellitus in palliative care patients. Eur J Palliat Care. 2003; 10: 186–188.
  18. McCoubrie R, Jeffrey D, Paton C, et al. Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care (Engl). 2005; 14(3): 244–248.
  19. Ford-Dunn S, Smith A, Quin J. Blood glucose levels in diabetic patients during the terminal phase: is continuation of treatment necessary? Palliat Med. 2004; 18: 161.
  20. Ford-Dunn S, Smith A, Quin J. [Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med. 2006; 20(3): 197–203.
  21. Modlińska A, Wolnik B. Chory z zaburzeniami kontroli glikemii w opiece paliatywnej. Med Paliat. 2013; 5: 1–7.
  22. Rodriguez A, Muller DC, Engelhardt M, et al. Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging. Metabolism. 2005; 54(4): 542–547.
  23. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 34(8): 535–542.
  24. Bays H. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther. 2013; 4(2): 195–220.
  25. Tahrani A, Barnett A, Bailey C. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013; 1(2): 140–151.
  26. Strojek K, Rokicka D, Szymborska-Kajanek A, et al. Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes? Clin Diabet. 2016; 5(3): 107–110.
  27. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
  28. Rotz ME, Ganetsky VS, Sen S, et al. Implications of incretin-based therapies on cardiovascular disease. Int J Clin Pract. 2015; 69(5): 531–549.
  29. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140–149.
  30. Ford–Dunn S, Smith A, Quin J. Management of diabetes during the last days of life a retrospective survey of dying patients in the hospital and hospice settings. Diabetic Med. 2004; 21: 83.
  31. Strojek K. Diabetologia. Praktyczny poradnik. Termedia, Poznań 2014: 199–207.
  32. End of Life Diabetes Care: Clinical Care Recommendations. Commissioned by Diabetes UK. Second Edition October 2013; p.7 2013.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl